IRWD Stock Overview
A healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
My Notes
Capture your thoughts, links and company narrative
Ironwood Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.94 |
| 52 Week High | US$15.70 |
| 52 Week Low | US$1.89 |
| Beta | 0.29 |
| 1 Month Change | -57.17% |
| 3 Month Change | -60.89% |
| 1 Year Change | -86.98% |
| 3 Year Change | -82.38% |
| 5 Year Change | -85.16% |
| Change since IPO | -83.35% |
Recent News & Updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 21
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
Oct 24Recent updates
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 21Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
Oct 24Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Aug 16Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
Jun 27Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Jun 20Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Feb 16Ironwood Pharmaceuticals: Capitalizing On GI Healthcare's Growing Potential
Jan 31Revenues Working Against Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price
Dec 19Ironwood Pharmaceuticals (NASDAQ:IRWD) Seems To Use Debt Rather Sparingly
Jul 25An Intrinsic Calculation For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Suggests It's 39% Undervalued
Apr 18Ironwood Pharmaceuticals (NASDAQ:IRWD) Could Easily Take On More Debt
Mar 28Ironwood Pharmaceuticals: Rinse, Wash And Repeat
Oct 05These 4 Measures Indicate That Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Using Debt Safely
Sep 28Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh
Jul 29Shareholder Returns
| IRWD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -15.7% | 3.5% | 0.6% |
| 1Y | -87.0% | 2.9% | 22.4% |
Return vs Industry: IRWD underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: IRWD underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| IRWD volatility | |
|---|---|
| IRWD Average Weekly Movement | 15.9% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: IRWD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IRWD's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 267 | Tom McCourt | www.ironwoodpharma.com |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.
Ironwood Pharmaceuticals, Inc. Fundamentals Summary
| IRWD fundamental statistics | |
|---|---|
| Market cap | US$337.66m |
| Earnings (TTM) | -US$2.46m |
| Revenue (TTM) | US$378.42m |
0.8x
P/S Ratio-126.0x
P/E RatioIs IRWD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRWD income statement (TTM) | |
|---|---|
| Revenue | US$378.42m |
| Cost of Revenue | US$125.41m |
| Gross Profit | US$253.01m |
| Other Expenses | US$255.48m |
| Earnings | -US$2.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.015 |
| Gross Margin | 66.86% |
| Net Profit Margin | -0.65% |
| Debt/Equity Ratio | -192.3% |
How did IRWD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 00:15 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ironwood Pharmaceuticals, Inc. is covered by 35 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |
| David Maris | BMO Capital Markets Equity Research |